IMUNON

IMUNON will present translational data from the phase‑2 OVATION 2 study of IMNN-001 at the SITC meeting in early November; a poster by Douglas V. Faller examines the remodeling of the tumor microenvironment. OVATION 2 showed a median overall survival benefit of 13 months and a median progression‑free survival benefit of 3 months in the IMNN-001 treatment arm, with additional benefit from PARP inhibitor maintenance therapy. The company is advancing the registrational phase‑3 OVATION 3 trial, which includes two planned interim analyses of the primary endpoint and could speed an FDA submission if successful. Financially the situation is rated weak: IMUNON reported a Q2 EPS miss of -$2.15 versus -$0.32 expected and has a high cash burn rate. » More on de.investing.com

Imunon reported a loss per share of $32.25 for the quarter ended June 30, 2025, compared to a loss of $7.65 per share in the same quarter last year. This marks a substantial increase in the quarterly loss year over year. No further details on revenue or outlook were provided. » More on finanzen.net

Imunon significantly missed earnings expectations in the second quarter of 2025, reporting an EPS of -$2.15, which led to a nearly 10% drop in its share price. Despite progress in cost reduction and the advancement of the OVATION III Phase 3 trial, the company continues to face ongoing net losses and financial challenges. Management is exploring strategic financing options to regain NASDAQ compliance and support international expansion. » More on de.investing.com